Podium to Practice: EHA 2026 – Lymphoma: EPCORE DLBCL-1
OR
Studies / Trials Discussed
S235 – RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
Co-Chairs
Speakers
Explore more from your favourite experts – click their name to access their entire library of content.
This program has been made possible through unrestricted support from Merck.
Studies/trials discussed:
S235 – RESULTS FROM EPCORE DLBCL-1: RANDOMIZED PHASE 3 STUDY OF EPCORITAMAB (EPCOR) VS INVESTIGATOR’S CHOICE CHEMOIMMUNOTHERAPY (CIT) IN PATIENTS WITH RELAPSED/REFRACTORY LARGE B-CELL LYMPHOMA (R/R LBCL)
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.